Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic

J Infect Dis. 2021 Mar 29;223(6):981-984. doi: 10.1093/infdis/jiaa789.

Abstract

Neutrophil extracellular traps (NETs) contribute to immunothrombosis and have been associated with mortality in coronavirus disease 2019 (COVID-19). We stimulated donor neutrophils with plasma from patients with COVID-19 and demonstrated that R406 can abrogate the release of NETs. These data provide evidence for how fostamatinib may mitigate neutrophil-associated mechanisms contributing to COVID-19 immunopathogenesis.

Trial registration: ClinicalTrials.gov NCT04579393.

Keywords: COVID-19; fostamatinib; immunothrombosis; neutrophil extracellular traps.

MeSH terms

  • COVID-19 / blood
  • COVID-19 / drug therapy*
  • COVID-19 / pathology
  • Extracellular Traps / drug effects*
  • Humans
  • Neutrophils / drug effects*
  • Oxazines / pharmacology*
  • Pyridines / pharmacology*
  • SARS-CoV-2 / isolation & purification

Substances

  • Oxazines
  • Pyridines
  • fostamatinib

Supplementary concepts

  • COVID-19 drug treatment

Associated data

  • ClinicalTrials.gov/NCT04579393